Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NI504
- Development stage
- Preclinical
- Lead developer
- Ono Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
NI504 is a monoclonal antibody currently in the discovery phase of development for the treatment of neurodegenerative disorders. Developed by Neurimmune in collaboration with Ono Pharmaceutical, the candidate was identified using Neurimmune's proprietary Reverse Translational Medicine (RTM) technology platform. This platform translates human immune memory into antibody therapeutics by identifying high-affinity antibodies from healthy elderly individuals or patients with resilient clinical phenotypes. While the specific biological target of NI504 has not been publicly disclosed, it is part of a broader pipeline focused on protein aggregation and central nervous system (CNS) pathologies.
Beyond the preview
Go deeper on NI504.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NI504.